Mounjaro vs Wegovy — an honest pharmacist's comparison

The short version

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist. Semaglutide (Wegovy) is a GLP-1 receptor agonist. In head-to-head trial data, average weight loss has been larger on tirzepatide. Semaglutide has a longer real-world track record and stronger cardiovascular outcome evidence. Both are MHRA-licensed for chronic weight management. Both require a structured programme. Either can be the right answer depending on tolerability, response, evidence priorities, supply, and cost. The decision is a clinical conversation, not a marketing one.

How they actually work

GLP-1 (glucagon-like peptide-1) is one of the gut hormones the body releases in response to food. It dampens appetite, slows gastric emptying, and improves insulin response. Semaglutide is a long-acting GLP-1 receptor agonist — it binds to that same receptor and stays in the system for about a week per dose, keeping the satiety signal on far longer than the body's own short-lived hormone.

Tirzepatide does the same thing — and then some. It's a single molecule designed to activate both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors at once. GIP is another gut hormone involved in satiety and energy regulation. The dual mechanism appears to amplify weight reduction and may also blunt some of the side-effect intensity per unit of effect.

That's the mechanism difference in one paragraph. Semaglutide: one receptor, well-understood, long history. Tirzepatide: two receptors at once, newer, larger average effect.

What the head-to-head data shows

SURMOUNT-5, published in 2025, was the first major head-to-head trial of tirzepatide versus semaglutide for weight loss in adults with obesity who didn't have diabetes. Over the trial period, average total body weight reduction was meaningfully larger on tirzepatide than on semaglutide. The proportion of participants achieving ≥15% and ≥20% weight loss was higher on tirzepatide too.

That's the headline. The caveats:

• Averages are averages — individual response varies enormously on both drugs.
• Trial doses don't always reflect real-world tolerated doses; not everyone gets to or stays at full dose.
• 'More weight loss' isn't automatically 'better' for everyone. Health outcomes, comorbidity control, side-effect burden, and sustainability all matter.
• Semaglutide has been on the market longer and has more robust cardiovascular outcome data (SELECT trial showed reduced major adverse cardiovascular events).

Side effects — where they diverge

Both drugs share the GLP-1-family side-effect profile: nausea, constipation, occasional reflux, mild fatigue, and reduced appetite (which is the point, not a side effect, but is often listed as one). Both can cause rare but serious effects including pancreatitis, gallbladder problems, and severe dehydration if vomiting is significant. Both carry contraindications around medullary thyroid cancer and MEN2.

Two practical differences worth noting:

• Nausea intensity per unit of effect. Anecdotally and in some trial signal, tirzepatide produces less nausea per unit of weight loss than semaglutide — possibly because the GIP activity offsets some of the GLP-1-driven GI effects. This isn't universal; some patients tolerate semaglutide better.
• Dose escalation length. Tirzepatide has a longer ladder (six potential dose steps vs five for semaglutide) which gives more room to find the right tolerated dose, but also a longer runway before reaching maximum effect.

Cardiovascular evidence

This is one area where the older drug has the stronger evidence. The SELECT trial (semaglutide) showed a statistically significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, independent of weight loss. That's a meaningful clinical signal.

Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT, comparing tirzepatide to dulaglutide in adults with type 2 diabetes) reported results in 2025 showing non-inferiority on major cardiovascular outcomes. A dedicated tirzepatide CVOT in adults with obesity without diabetes is ongoing. So: semaglutide has the clearer CV outcome data for obesity right now; tirzepatide's data is robust but more limited in the obesity-without-diabetes specifically.

If you have established cardiovascular disease, this matters more for the decision. If you don't, it matters less.

Cost and supply, plainly

Both medications have had supply pressure since launch. As of 2026, supply has been steadier across both. Pricing varies by dose, by supplier, and by what's included in the programme.

The principle we apply in consultations: don't compare pen prices. Compare programme prices. A pen-only price quoted somewhere cheap is usually not a complete service. Responsible private prescribing bundles consultation, monitoring, dietary support, and access to a clinician for side effects. If a service is just selling pens, that's a supply chain — not weight management care.

How to think about choosing

If you're choosing between them, the questions worth working through with a clinician are:

• How big is your weight loss goal? Larger goals tilt the conversation toward tirzepatide on average; modest goals are well-served by semaglutide.
• How important is cardiovascular protection? If you have established CV disease, semaglutide has clearer outcome data for now.
• How sensitive are you to nausea? If GI tolerability is a concern, tirzepatide may have a small edge — but neither is nausea-free.
• Have you used either before? Past tolerability is often the best predictor of future tolerability.
• What's available, where, at what cost, and with what wraparound? The 'best' molecule is the one you can actually start, stay on, and be supported on.

What both still require

Whichever you choose, the prescription is one component of a structured weight management programme. That means a clinical consultation before initiation, dietary and behavioural support, monitoring during escalation, side effect management, and a plan for maintenance and discontinuation. MHRA standards now require this, and good services were doing it anyway.

The medication gives you a window — usually 12–18 months of strong appetite control. The programme is what helps you use that window to rebuild eating, activity, and behavioural patterns that hold when you taper or stop. Without that, you've bought a year and a half of weight loss that gradually returns. With it, you've bought a chance to reset your baseline.

The next step

The most useful single step is a 20–30 minute consultation: it's where eligibility gets confirmed, the choice between tirzepatide and semaglutide stops being abstract, and you find out which structured programme actually fits how you live. We've prescribed both for years now and our role isn't to push one product — it's to help you choose the one most likely to work for you and stay sustainable.